Want Extra Out Of Your Life? Lung Cancer Treatment Singapore

In the worldwide, randomized, open-label Part IIb LUX-Lung 7 (LL7) trial (1), the irreversible ErbB family blocker afatinib significantly improved efficacy versus gefitinib throughout a spread of clinically related endpoints, reminiscent of progression-free survival, time-to-therapy failure, and accurate response price. Survival curves from the LUX-Lung three trial (afatinib versus pemetrexed-cisplatin chemotherapy) have been extrapolated beyond the trial interval to estimate the underlying development-free survival and total survival parametric distributions. In the base-case evaluation, the ICER for afatinib versus pemetrexed-cisplatin was SG$137,648 per high quality-adjusted life-year (QALY) gained and SG$109,172 per life-12 months gained. Patients with EGFR-activating mutations in supe

Read More